<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To define the role of magnetization transfer imaging (MTI) in detecting subclinical central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) lesions in <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (PAPS) </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: Ten non-<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> PAPS patients were compared to 10 CNS PAPS patients and 10 age- and sex-matched controls </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> PAPS patients met Sapporo criteria </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> subjects underwent conventional MRI and complementary MTI analysis to compose histograms </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> viability was determined according to the magnetization transfer ratio (MTR) by mean pixel intensity (MPI) and the mean peak height (MPH) </plain></SENT>
<SENT sid="5" pm="."><plain>Volumetric cerebral measurements were assessed by brain parenchyma factor (BPF) and total/cerebral volume </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: MTR histograms analysis revealed that MPI was significantly different among groups (P &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>Non-<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> PAPS had a higher MPI than <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> PAPS (30.5 +/- 1.01 vs. 25.1 +/- 3.17 percent unit (pu); P &lt; 0.05) although lower than controls (30.5 +/- 1.01 vs. 31.20 +/- 0.50 pu; P &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>MPH in non-<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> PAPS (5.57 +/- 0.20% (1/pu)) was similar to controls (5.63 +/- 0.20% (1/pu), P &gt; 0.05) and higher than <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> PAPS (4.71 +/- 0.30% (1/pu), P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>A higher peak location (PL) was also observed in the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> PAPS group in comparison with the other groups (P &lt; 0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, a lower BPF was found in non-<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> PAPS compared to controls (0.80 +/- 0.03 vs. 0.84 +/- 0.02 units; P &lt; 0.05) but similar to <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> PAPS (0.80 +/- 0.03 vs. 0.79 +/- 0.05 units; P &gt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: Our findings suggest that non-<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> PAPS patients have subclinical cerebral damage </plain></SENT>
<SENT sid="12" pm="."><plain>The long-termclinical relevance of MTI analysis in these patients needs to be defined by prospective studies </plain></SENT>
</text></document>